Last reviewed · How we verify
Active Ulcerative Colitis — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| TNF Inhibitor | tnf-inhibitor | Pfizer | Monoclonal Antibody | TNF-alpha | ||
| Induction- PF-06480605 150 mg SC Q4W | induction-pf-06480605-150-mg-sc-q4w | Pfizer | JAK inhibitor | JAK pathway |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 2 drugs in Active Ulcerative Colitis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Active Ulcerative Colitis:
- Active Ulcerative Colitis treatment updates — RSS
- Active Ulcerative Colitis treatment updates — Atom
- Active Ulcerative Colitis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Active Ulcerative Colitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/active-ulcerative-colitis. Accessed 2026-06-10.
Related
- Active Ulcerative Colitis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing